So How Exactly Does Omipalisib Perform?

Patients unfit for cisplatin were defined as those who had ECOG performance status ��2, creatinine clearance http://www.selleckchem.com/products/bay-57-1293.html or biologic therapy were excluded. A total of 41 patients were randomized to CP, and 44 http://www.selleck.cn/products/CAL-101.html to M-VAC. Patients received paclitaxel at a dose of 225?mg/m2 and carboplatin (targeted AUC of 6) given every 21?days or the standard M-VAC dosage. Response rates (28% vs 35%), PFS (8.7 vs 5.2?months) and OS (15 vs 14?months) were statistically similar for both treatment arms.[19] Several other phase?II studies have reported a response rate of 52% and a median survival of 8.5?months.[23] A randomized phase?II study was carried out by Bellmunt et?al. that compared M-VAC with MCAVI. In that study, the M-VAC arm had better OS (16 vs 9?months) and response http://www.selleckchem.com/products/gsk2126458.html rate (52% vs 39%). Even though MCAVI was less toxic than M-VAC, it was less effective and hence the authors concluded that MCAVI should be reserved for cisplatin-ineligible patients only.[20] In another study, the effects of carboplatin, paclitaxel and GC were evaluated in 49 patients. Each patient received paclitaxel 200?mg/m2, carboplatin (target AUC 5) on day?1, and GC 800?mg/m2 on days?1 and 8, repeated every 21?days. Major toxicities noted were neutropenia being the most common, followed by thrombocytopenia and anemia. A total of 47 of the 49 patients were assessed for response. A total of 15 (32%) patients experienced a complete response, and 17 (36%) patients experienced partial response. The median survival was 15?months, with a 1-year survival of 59%.[21] In patients with impaired renal function, a carboplatin-based regimen was explored in a phase?II study of dose-dense doxorubicin plus GC, followed by paclitaxel plus carboplatin, in a similarly cisplatin-ineligible population of patients with metastatic urothelial carcinoma based on renal impairment or a prior history of nephrectomy. Patients received treatment with doxorubicin plus GC every other week for five cycles followed by paclitaxel plus carboplatin weekly for 12?weeks. Of the 25 patients enrolled in that study, 28% experienced grade?3�C4 neutropenia and 16% had grade?3�C4 thrombotic events.